You are here

Biological Therapeutics

From patented antibodies to tumour associated cell surface markers. We have a diverse portfolio with the opportunity to licence agents in pre-clinical to Phase II clinical development.

ɑvß6 integrin is a promising target for cancer therapy. It plays an active role in tumour progression and its high expression is linked to poor prognosis in many tumour types.

Read more